Will COVID nasal sprays soon help prevent and treat infection? Virology and infectious diseases expert Dr Lara Herrero looks at the latest science surrounding a potential new treatment.
What can we expect from the latest COVID wave? How long is the new wave likely to last? As case numbers continue to rise, UNSW academic James Wood looks at the most probable outcomes.
MBS clarity needed to boost long COVID care: RACGP Medicare flaws must be addressed to help mitigate the ‘far reaching’ impact of long COVID, a college submission to Parliament has said.
Long COVID risk similar for kids and adults: Study With Australia in the midst of a new wave of infections, research has revealed the extent of post-COVID morbidity in children and adolescents.
Second bivalent booster receives ATAGI recommendation The vaccine will become available in December and is recommended for people who have not had their first or second booster doses.
Vast majority of Australian population has had COVID: Seroprevalence survey Upwards of eight in 10 people have at some point likely contracted the disease, which is now the third leading cause of death nationwide.
‘A positive step’: oral antivirals confirmed for Doctor’s Bag After extensive RACGP lobbying, GPs now have enhanced access to COVID-19 oral antiviral treatments for urgent use among at-risk patients.
Study identifies link between COVID-19 and Parkinson’s Researchers say the virus aggravates brain cells similar to neurodegenerative conditions, flagging potential future risk, but also treatments.
Survey hints at increasing long COVID burden Half of the nearly 2200 people surveyed by Lung Foundation Australia reported ongoing symptoms more than four weeks after their initial infection.
New variants expected to supplant BA.5 in Australia Both XBB and BQ.1 possess a growth advantage over previous COVID strains, but there is no evidence to suggest either variant is more severe.